Telisotuzumab vedotin Antibody
Telisotuzumab vedotin (ABBV-399) is a c-Met-targeting antibody-drug conjugate (ADC) developed for research applications. It demonstrates antitumor activity in preclinical models of non-small cell lung cancer (NSCLC), including studies involving c-Met overexpressing squamous cell carcinoma, supporting its investigation for recurrent disease.
Product Specifications
Product Name Alternative
ADCs, ABBV 399, ABBV399, ABBV-399, ABT399, ABT 399, AntibodyDrugConjugates, AntibodyDrugConjugates (ADCs), Antibody-Drug Conjugates, AntibodyDrug Conjugates (ADCs), Telisotuzumab vedotin
Target
C-Met/HGFR, Antibody-Drug Conjugates (ADCs)
Clonality
Recombinant
Conjugation
Unconjugated
Field of Research
Signal Transduction
Concentration
7.15 mg/mL
Purity
>95.0% (May vary between batches)
Molecular Weight
151.37 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
